Abstract:Antonio F. Martinez-Monseny Department of Genetic and Molecular Medicine/IPER, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain Comment on: Li Q, Chen Z, Wang J, et al . Molecular Diagnostic Yield of Exome Sequencing and Chromosomal Microarray in Short Stature: A Systematic Review and Meta-Analysis. JAMA Pediatr 2023;177:1149-57. Submitted Feb 19, 2024. Accepted for publication Apr 17, 2024. Published online May 20, 2024. doi: 10.21037/tp-24-46 In the realm of contemporary medicine, the pursuit of precision and accuracy continues to drive advancements in genetic testing. For paediatric patients presenting with short stature, a condition often influenced by a myriad of genetic factors, the diagnostic landscape has undergone a transformation with the emergence of chromosomal microarray analysis (CMA) and exome sequencing (ES). This approach not only expedites the diagnostic process but also provides the opportunity to identify common genetic patterns in individuals with short stature, paving the way for more personalized and effective treatments. In this editorial commentary, I will analyze the recent paper authored by Li et al. , delving into the dynamic role of contemporary technologies in deciphering the genetic intricacies associated with short stature (1). The exploration encompasses an in-depth assessment of their diagnostic performance, challenges encountered, and the significant potential they bear for advancing patient care. This editorial commentary also aims to provide a comprehensive analysis of the comparative aspects of these two genetic testing modalities, delving into the specific advantages and limitations of each of them in the context of short stature. Short stature, defined as a height that is less than 2 standard deviations (SDs) from the mean for the respective age and gender (1,2). The aetiology of short stature is multifactorial and can result from genetic factors, hormonal factors such as growth hormone, thyroid hormones, and cortisol, and a spectrum of environmental factors (prenatal and postnatal), or a combination of both. While familial short stature and constitutional growth delay are common conditions of short stature, a subset of cases involves genetic syndromes and disorders that necessitate a comprehensive genetic evaluation for accurate diagnosis and appropriate management, particularly in cases of severe short stature with associated dysmorphic features. A significant proportion of short stature cases have an underlying genetic aetiology with more than 250 genes implicated in its pathogenesis such as SHOX , GH1 , IGF1 , IGF1R , GHR or FGFR3 , among others. Therefore, identifying the genetic basis of short stature is critical for establishing accurate diagnoses, informing prognosis, and guiding personalized management strategies (1-6). The utility of ES and CMA in the study of short stature extends beyond diagnosis. The information obtained through these advanced techniques also opens the door to potential therapeutic research. The systematic review and meta-analysis from Li et al. , involving 20 studies and a total of 2,420 patients with short stature, found an overall diagnostic yield of 27.1% for ES and 13.6% for CMA. No statistically significant difference was observed between first-tier and last-resort groups for either ES or CMA. These results provide evidence supporting the diagnostic efficacy of ES and CMA in patients with short stature, trying to serve as a valuable guidance for clinicians in recommending genetic tests. I think that while the methodology of the study regarding included and excluded articles seems appropriate, a significant limitation lies in the great heterogeneity observed within the spectrum of short stature. Most classifications of short stature consider factors to guide the diagnosis and management of patients with short stature, as they help identify patients with a higher suspicion of syndromic causes, and the diagnostic yield based on genetic testing. Some of the most frequent genetic syndromes associated with short stature are: Turner, Down, 22q11.2 deletion, Noonan, Williams, Silver-Russell and Prader-Willi syndromes, SHOX deficiency and achondroplasia, among others (2-4). CMA is a genomic technique used to detect chromosomal abnormalities and copy number variations (CNVs) across the entire genome. It has traditionally served as a screening tool in the genetic diagnostic arsenal. It excels in detecting submicroscopic chromosomal imbalances and CNV, providing a comprehensive view of the genome (7,8). CMA is the most widely used genetic screening test that rules out various genetic syndromes associated with short stature. Over time, in many types of short stature and based on associated clinical signs, it has been losing strength and giving way to ES. ES is a genomic technique of next-g -Abstract Truncated-

Diagnostic Whole Exome Sequencing in Patients with Short Stature

Clinical profiles and molecular genetic analyses of 98 Chinese children with short statures

Molecular diagnosis of patients with syndromic short stature identified by trio whole-exome sequencing

Exome sequencing reveals genetic architecture in patients with isolated or syndromic short stature

Preliminary investigation into the genetic etiology of short stature in children through whole exon sequencing of the core family

Genetic Evaluation of 114 Chinese Short Stature Children in the Next Generation Era: a Single Center Study.

The application of whole-exome sequencing in the early diagnosis of rare genetic diseases in children: a study from Southeastern China

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Pathogenic gene screening in 91 Chinese patients with short stature of unknown etiology with a targeted next-generation sequencing panel.

Whole Exome Sequencing Uncovered the Genetic Architecture of Growth Hormone Deficiency Patients

Molecular diagnosis is an important indicator for response to growth hormone therapy in children with short stature

Unravelling short stature in pediatrics: the crucial role of genetic perspective

Clinical Application of Whole Exome Sequencing for Monogenic Disorders in PICU of China

Clinical use of whole exome sequencing in children with developmental delay/intellectual disability

Identification of 11 Potentially Relevant Gene Mutations Involved in Growth Retardation, Intellectual Disability, Joint Contracture, and Hepatopathy

Whole Exome Sequencing Aids the Diagnosis of Fetal Skeletal Dysplasia

Genetic studies of 77 cases of short stature with unknown etiology

Whole Exome Sequencing for Non-Selective Pediatric Patients with Hyperlipidemia

A study on genotypes and phenotypes of short stature caused by epigenetic modification gene variants

Prenatal Trio-Based Whole Exome Sequencing in Fetuses with Abnormalities of the Skeletal System

Genomic Basis of Syndromic Short Stature in an Algerian Patient Cohort.